Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple Sclerosis Journal

Volumn 18, Issue 2, 2012, Pages 143-152

  Sørensen, Per Soelberg ^a   Bertolotto, Antonio ^b   Edan, Gilles ^c   Giovannoni, Gavin ^d   Gold, Ralf ^e   Havrdova, Eva ^f   Kappos, Ludwig ^g   Kieseier, Bernd C ^h   Montalban, Xavier ⁱ   Olsson, Tomas ^j  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Centro Riferimento Regionale Sclerosi Multipla and Neurobiologica Clinica   (Italy)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ST JOSEF HOSPITAL   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Disease modifying therapies; multiple sclerosis; natalizumab; PML; progressive multifocal leukoencephalopathy; risk assessment; Tysabri

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; PLACEBO;

ALGORITHM; ANTIBODY DETECTION; DECISION MAKING; DISEASE COURSE; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; JC VIRUS; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 84856724312     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511435105     Document Type: Review

References (41)

1. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004 ; 4: 571-580 (Pubitemid 38890585)
2. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
4. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
5. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009 ; 9: 625-636
6. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010 ; 61: 35-47
7. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008 ; 67:
8. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009 ; 60: 3761-3765
9. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010 ; 9: 425-437
10. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 ; 10: 816-824
11. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 ; 353: 369-374 (Pubitemid 41132341)
12. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 ; 353: 375-381 (Pubitemid 41132342)
13. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005 ; 353: 362-368 (Pubitemid 41132340)
14. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 ; 354: 924-933
15. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971 ; 1: 1257-1260
16. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009 ; 199: 837-846
17. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009 ; 5: e1000363
18. Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst. 2003 ; 95: 1522-1530 (Pubitemid 37322095)
19. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003 ; 71: 115-123 (Pubitemid 37121921)
20. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol. 2003 ; 84: 1499-1504 (Pubitemid 36675520)
21. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol. 2001 ; 49: 636-642 (Pubitemid 32429790)
22. Verbeeck J, Van AG, Ryding J, Wollants E, Rans K, Vermeire S, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut. 2008 ; 57: 1393-1397
23. Matos A, Duque V, Beato S, da Silva JP, Major E, Melico-Silvestre A. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol. 2010 ; 82: 494-504
24. Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983 ; 147: 676-684 (Pubitemid 13088241)
25. Tan CS, Chen Y, Viscidi RP, Kinkel RP, Stein MC, Koralnik IJ. Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol. 2010 ; 9: 565-566
26. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009 ; 5: e1000368
27. Clifford DB, De LA, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
28. Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 ; 361: 1081-1087
29. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009 ; 361: 1075-1080
30. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009 ; 8: 28-31
31. Sandrock A, Hotermans C, Richman S. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab treatment duration, and anti-JCF antibody status. Neurology. 2011 ; 76: A248
32. Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 ; 76: 1697-1704
33. Kappos L, Foley J, Gold R, Olsson T, Vermersch P, Bozic C, et al. Overview of survival outcome and functional status in postmarketing cases of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler J. 2011 ; 17: S131
34. Vermersch P, Foley J, Gold R, Kappos L, Olsson T, Cadavid D, et al. Overview of survival outcome and functional status in postmarketing cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab. Eur J Neurol. 2011 ; 18: 58
35. Subramanyam M, Plavina T, Lee S, Njenga M, Gorelik L, Natarajan G, et al. Anti-JCV antibodies are consistently detected prior to and after PML diagnosis in natalizumab-treated MS patients. Neurology. 2011 ; 76: A636 - A637
36. Sandrock A, Hotermans C, Richman S, Natarajan A, Lee S, Plavina T, et al. Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab. J Neurol. 2011 ; 258: S23
37. Bozic C, cristiano L, Hyde R. Utilization and safety of natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2010 ; 16: S315
38. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
39. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JC virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mult Scler J. 2011 ; 17: S451
40. Bozic C, Richman S, Plavina T. Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1. Neurology. 2011 ; 76: A598
41. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology. 2008 ; 71: 357-364